{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:51:20Z","timestamp":1792590680130,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with an increasing burden of metabolic dysfunction-associated steatotic liver disease-associated HCC in Western populations. In treating HCC, recurrence after curative-intent therapy remains common, creating a compelling rationale for perioperative systemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Landmark Series review examines the pivotal studies that have shaped the surgical and perioperative management of HCC, tracing the evolution from principles of resectability to contemporary adjuvant and neoadjuvant immune-based strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The development of perioperative therapy has been defined by both landmark negative trials and emerging evidence of efficacy. The STORM trial demonstrated that sorafenib's activity in advanced HCC did not translate into benefit after resection or ablation. The IMbrave050 trial subsequently demonstrated an early recurrence-free survival advantage with adjuvant atezolizumab plus bevacizumab that was not sustained with longer follow-up evaluation, whereas the KEYNOTE-937 trial failed to demonstrate benefit with adjuvant pembrolizumab. In contrast, early-phase neoadjuvant immune checkpoint inhibitor-based studies have demonstrated feasibility and meaningful pathologic responses, and the CARES-009 trial provided the first randomized phase III evidence of improved event-free survival with a perioperative immune checkpoint inhibitor\u2013antiangiogenic strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Perioperative management of HCC is evolving toward an integrated, multidisciplinary treatment paradigm. Although no broadly applicable adjuvant systemic therapy has been established, emerging perioperative strategies provide proof of concept that systemic therapy may improve outcomes for selected patients. Future progress will depend on biomarker-driven patient selection, molecular residual disease assessment, standardized pathologic response criteria, and clinical trials identifying which patients require perioperative therapy and when treatment should be delivered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20690-5","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:37:44Z","timestamp":1792589864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Landmark Series: Perioperative Management of Hepatocellular Carcinoma"],"prefix":"10.1245","author":[{"given":"Skylar L.","family":"Nahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Yopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"20690_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70090","volume":"76","author":"H Sung","year":"2026","unstructured":"Sung H, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026;76:e70090. https:\/\/doi.org\/10.3322\/caac.70090.","journal-title":"CA Cancer J Clin"},{"key":"20690_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Primers."},{"key":"20690_CR3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450\u201362. https:\/\/doi.org\/10.1056\/NEJMra1713263.","journal-title":"N Engl J Med."},{"key":"20690_CR4","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365. https:\/\/doi.org\/10.1097\/HEP.0000000000000466.","journal-title":"Hepatology."},{"key":"20690_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","volume":"84","author":"M Reig","year":"2026","unstructured":"Reig M, et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update. J Hepatol. 2026;84:631\u201354. https:\/\/doi.org\/10.1016\/j.jhep.2025.10.020.","journal-title":"J Hepatol."},{"key":"20690_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/s0168-8278(02)00360-4","volume":"38","author":"H Imamura","year":"2003","unstructured":"Imamura H, et al. Risk factors contributing to early- and late-phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200\u20137. https:\/\/doi.org\/10.1016\/s0168-8278(02)00360-4.","journal-title":"J Hepatol."},{"key":"20690_CR7","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2018.08.027","volume":"69","author":"AWH Chan","year":"2018","unstructured":"Chan AWH, et al. Development of pre- and postoperative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69:1284\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2018.08.027.","journal-title":"J Hepatol."},{"key":"20690_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/SLA.0000000000006386","volume":"280","author":"CJ Wehrle","year":"2018","unstructured":"Wehrle CJ, et al. Tumor mutational burden from circulating tumor DNA predicts recurrence of hepatocellular carcinoma after resection: an emerging biomarker for surveillance. Ann Surg. 2018;280:504\u201313. https:\/\/doi.org\/10.1097\/SLA.0000000000006386.","journal-title":"Ann Surg."},{"key":"20690_CR9","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med."},{"key":"20690_CR10","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070.","journal-title":"NEJM Evid."},{"key":"20690_CR11","unstructured":"Amin MB, Edge SB, Greene FL. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. Springer; 2017."},{"key":"20690_CR12","unstructured":"Network NCC. NCCN clinical practice guidelines in oncology: hepatocellular carcinoma. 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hcc.pdf."},{"key":"20690_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, et al. Hepatobiliary cancers, version 2.2021. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:541\u201365. https:\/\/doi.org\/10.6004\/jnccn.2021.0022.","journal-title":"J Natl Compr Canc Netw."},{"key":"20690_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","volume":"36","author":"A Vogel","year":"2025","unstructured":"Vogel A, et al. Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment, and follow-up. Ann Oncol. 2025;36:491\u2013506. https:\/\/doi.org\/10.1016\/j.annonc.2025.02.006.","journal-title":"Ann Oncol."},{"key":"20690_CR15","doi-asserted-by":"publisher","first-page":"xv","DOI":"10.1016\/j.soc.2023.07.002","volume":"33","author":"AC Yopp","year":"2024","unstructured":"Yopp AC, Majella Doyle MB. Hepatocellular carcinoma. Surg Oncol Clin North Am. 2024;33:xv\u2013xvi. https:\/\/doi.org\/10.1016\/j.soc.2023.07.002.","journal-title":"Surg Oncol Clin North Am."},{"key":"20690_CR16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2468-1253(24)00434-5","volume":"10","author":"CTJ Magyar","year":"2025","unstructured":"Magyar CTJ, et al. Precision surgery for hepatocellular carcinoma. Lancet Gastroenterol Hepatol. 2025;10:350\u201368. https:\/\/doi.org\/10.1016\/S2468-1253(24)00434-5.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"20690_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001834","author":"AG Singal","year":"2026","unstructured":"Singal AG, et al. BEACON-HCC: best evidence and North American consensus on treatment allocation for hepatocellular carcinoma. Hepatology. 2026. https:\/\/doi.org\/10.1097\/HEP.0000000000001834.","journal-title":"Hepatology."},{"key":"20690_CR18","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/1097-0142(20000801)89:3<500::AID-CNCR4>3.0.CO;2-O","volume":"89","author":"RT Poon","year":"2000","unstructured":"Poon RT, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500\u20137.","journal-title":"Cancer."},{"key":"20690_CR19","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","volume":"16","author":"J Bruix","year":"2015","unstructured":"Bruix J, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(15)00198-9.","journal-title":"Lancet Oncol."},{"key":"20690_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/gutjnl-2018-316408","volume":"68","author":"R Pinyol","year":"2019","unstructured":"Pinyol R, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 2019;68:1065\u201375. https:\/\/doi.org\/10.1136\/gutjnl-2018-316408.","journal-title":"Gut."},{"key":"20690_CR21","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1835\u201347. https:\/\/doi.org\/10.1016\/S0140-6736(23)01796-8.","journal-title":"Lancet."},{"key":"20690_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jhep.2026.01.006","volume":"84","author":"A Yopp","year":"2026","unstructured":"Yopp A, et al. Updated data from IMbrave050: adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. J Hepatol. 2026;84:1102\u201311. https:\/\/doi.org\/10.1016\/j.jhep.2026.01.006.","journal-title":"J Hepatol."},{"key":"20690_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jhep.2025.08.042","volume":"84","author":"E Mauro","year":"2026","unstructured":"Mauro E, et al. Strategies to address non-proportional hazards between survival curves: lessons from phase III trials in hepatocellular carcinoma. J Hepatol. 2026;84:567\u201377. https:\/\/doi.org\/10.1016\/j.jhep.2025.08.042.","journal-title":"J Hepatol."},{"key":"20690_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1200\/JCO.2026.44.2_suppl.477","volume":"44","author":"SL Chan","year":"2026","unstructured":"Chan SL, et al. Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: the phase 3 keynote-937 study. J Clin Oncol. 2026;44:477\u2013477. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.477.","journal-title":"J Clin Oncol."},{"key":"20690_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","volume":"30","author":"K Wang","year":"2024","unstructured":"Wang K, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat Med. 2024;30:708\u201315. https:\/\/doi.org\/10.1038\/s41591-023-02786-7.","journal-title":"Nat Med."},{"key":"20690_CR26","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22:977\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00252-7.","journal-title":"Lancet Oncol."},{"key":"20690_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet JM, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024;21:294\u2013311. https:\/\/doi.org\/10.1038\/s41571-024-00868-0.","journal-title":"Nat Rev Clin Oncol."},{"key":"20690_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","volume":"7","author":"TU Marron","year":"2022","unstructured":"Marron TU, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:219\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(21)00385-X.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"20690_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12885-021-08033-x","volume":"21","author":"DJ Pinato","year":"2021","unstructured":"Pinato DJ, et al. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer. 2021;21:301. https:\/\/doi.org\/10.1186\/s12885-021-08033-x.","journal-title":"BMC Cancer."},{"key":"20690_CR30","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","volume":"7","author":"AO Kaseb","year":"2022","unstructured":"Kaseb AO, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:208\u201318. https:\/\/doi.org\/10.1016\/S2468-1253(21)00427-1.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"20690_CR31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","volume":"2","author":"WJ Ho","year":"2021","unstructured":"Ho WJ, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021;2:891\u2013903. https:\/\/doi.org\/10.1038\/s43018-021-00234-4.","journal-title":"Nat Cancer."},{"key":"20690_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004656","author":"Y Xia","year":"2022","unstructured":"Xia Y, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-004656.","journal-title":"J Immunother Cancer."},{"issue":"16_suppl","key":"20690_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4120","volume":"41","author":"YL Cui","year":"2023","unstructured":"Cui YL, et al. Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: a prospective, single-arm, phase 2 study. J Clin Oncol. 2023;41(16_suppl):4120. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.4120.","journal-title":"J Clin Oncol."},{"key":"20690_CR34","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/s41467-025-68108-2","volume":"17","author":"L Chen","year":"2026","unstructured":"Chen L, et al. Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial. Nat Commun. 2026;17:1358. https:\/\/doi.org\/10.1038\/s41467-025-68108-2.","journal-title":"Nat Commun."},{"key":"20690_CR35","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/S0140-6736(25)01720-9","volume":"406","author":"Z Wang","year":"2025","unstructured":"Wang Z, et al. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial. Lancet. 2025;406:2089\u201399. https:\/\/doi.org\/10.1016\/S0140-6736(25)01720-9.","journal-title":"Lancet."},{"issue":"4","key":"20690_CR36","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","volume":"143","author":"C Duvoux","year":"2012","unstructured":"Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S. Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143(4):986\u201394.","journal-title":"Gastroenterology."},{"key":"20690_CR37","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.transproceed.2023.03.064","volume":"55","author":"FC Kuo","year":"2023","unstructured":"Kuo FC, et al. Optimizing the safe washout period for liver transplantation following immune checkpoint inhibitors with atezolizumab, nivolumab, or pembrolizumab. Transplant Proc. 2023;55:878\u201383. https:\/\/doi.org\/10.1016\/j.transproceed.2023.03.064.","journal-title":"Transplant Proc."},{"key":"20690_CR38","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s10620-010-1482-0","volume":"56","author":"J Chen","year":"2011","unstructured":"Chen J, et al. Survival after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci. 2011;56:1626\u201333. https:\/\/doi.org\/10.1007\/s10620-010-1482-0.","journal-title":"Dig Dis Sci."},{"key":"20690_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1067\/msy.2002.121892","volume":"131","author":"JM Regimbeau","year":"2002","unstructured":"Regimbeau JM, et al. Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery. 2002;131:311\u20137. https:\/\/doi.org\/10.1067\/msy.2002.121892.","journal-title":"Surgery."},{"key":"20690_CR40","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.hpb.2017.04.010","volume":"19","author":"X Feng","year":"2017","unstructured":"Feng X, et al. A double-blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence. HPB Oxford. 2017;19:667\u201374. https:\/\/doi.org\/10.1016\/j.hpb.2017.04.010.","journal-title":"HPB Oxford."},{"key":"20690_CR41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/00000658-200004000-00014","volume":"231","author":"RT Poon","year":"2000","unstructured":"Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg. 2000;231:544\u201351. https:\/\/doi.org\/10.1097\/00000658-200004000-00014.","journal-title":"Ann Surg."},{"key":"20690_CR42","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s11605-019-04275-0","volume":"24","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras DI, et al. Effect of surgical margin width on patterns of recurrence among patients undergoing R0 hepatectomy for T1 hepatocellular carcinoma: an international multi-institutional analysis. J Gastrointest Surg. 2020;24:1552\u201360. https:\/\/doi.org\/10.1007\/s11605-019-04275-0.","journal-title":"J Gastrointest Surg."},{"key":"20690_CR43","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1007\/s11605-014-2667-1","volume":"18","author":"N Amini","year":"2014","unstructured":"Amini N, et al. Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Surg. 2014;18:2136\u201348. https:\/\/doi.org\/10.1007\/s11605-014-2667-1.","journal-title":"J Gastrointest Surg."},{"key":"20690_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.suronc.2020.12.011","volume":"36","author":"PM Kemp Bohan","year":"2021","unstructured":"Kemp Bohan PM, et al. Lymph node sampling in resectable hepatocellular carcinoma: national practice patterns and predictors of positive lymph nodes. Surg Oncol. 2021;36:138\u201346. https:\/\/doi.org\/10.1016\/j.suronc.2020.12.011.","journal-title":"Surg Oncol."},{"key":"20690_CR45","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/SLA.0000000000001413","volume":"263","author":"R Ciria","year":"2016","unstructured":"Ciria R, Cherqui D, Geller DA, Briceno J, Wakabayashi G. Comparative short-term benefits of laparoscopic liver resection: 9000 cases and climbing. Ann Surg. 2016;263:761\u201377. https:\/\/doi.org\/10.1097\/SLA.0000000000001413.","journal-title":"Ann Surg."},{"key":"20690_CR46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamasurg.2022.5697","volume":"158","author":"F Di Benedetto","year":"2023","unstructured":"Di Benedetto F, et al. Safety and efficacy of robotic vs open liver resection for hepatocellular carcinoma. JAMA Surg. 2023;158:46\u201354. https:\/\/doi.org\/10.1001\/jamasurg.2022.5697.","journal-title":"JAMA Surg."},{"key":"20690_CR47","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jhep.2024.06.018","volume":"81","author":"C Fuster-Anglada","year":"2024","unstructured":"Fuster-Anglada C, et al. Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection. J Hepatol. 2024;81:995\u20131004. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.018.","journal-title":"J Hepatol."},{"key":"20690_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.759565","volume":"12","author":"L Chen","year":"2021","unstructured":"Chen L, Zhou Q, Liu J, Zhang W. CTNNB1 alternation is a potential biomarker for immunotherapy prognosis in patients with hepatocellular carcinoma. Front Immunol. 2021;12:759565. https:\/\/doi.org\/10.3389\/fimmu.2021.759565.","journal-title":"Front Immunol."},{"key":"20690_CR49","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","volume":"25","author":"JJ Harding","year":"2019","unstructured":"Harding JJ, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25:2116\u201326. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2293.","journal-title":"Clin Cancer Res."},{"key":"20690_CR50","doi-asserted-by":"publisher","first-page":"HEP39","DOI":"10.2217\/hep-2020-0034","volume":"8","author":"M Wong","year":"2021","unstructured":"Wong M, et al. Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma. Hepat Oncol. 2021;8:HEP39. https:\/\/doi.org\/10.2217\/hep-2020-0034.","journal-title":"Hepat Oncol."},{"key":"20690_CR51","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/jgh3.12660","volume":"5","author":"S Mukai","year":"2021","unstructured":"Mukai S, et al. Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. JGH Open. 2021;5:1266\u201374. https:\/\/doi.org\/10.1002\/jgh3.12660.","journal-title":"JGH Open."},{"key":"20690_CR52","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450\u20136. https:\/\/doi.org\/10.1038\/s41586-021-03362-0.","journal-title":"Nature."},{"key":"20690_CR53","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","volume":"25","author":"A D\u2019Alessio","year":"2024","unstructured":"D\u2019Alessio A, et al. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 2024;25:1465\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(24)00457-1.","journal-title":"Lancet Oncol."},{"key":"20690_CR54","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41416-025-03296-8","volume":"134","author":"IR Buonopane","year":"2026","unstructured":"Buonopane IR, et al. Circulating tumour DNA for a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: a systematic review and meta-analysis. Br J Cancer. 2026;134:699\u2013706. https:\/\/doi.org\/10.1038\/s41416-025-03296-8.","journal-title":"Br J Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20690-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20690-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20690-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:37:45Z","timestamp":1792589865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20690-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":54,"alternative-id":["20690"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20690-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"14 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}